[ET Net News Agency, 9 April 2021] Macquarie raised its target price for 3SBio (01530)
to HK$13.08 and maintained its "outperform" rating.
The research house said the market may need a bit more time to brush off the lacklustre
earnings in 2020 and negative impact of policy on 3SBio's current top products. However,
previous investments and R&D help bring an early-stage pipeline (interleukins and
bispecific) into the clinical stage. It believes this should excite investors again and
help re-rate the stock to its previous level and potentially more. (RC)